{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:35Z","timestamp":1790395475745,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["FIS PI16\/02057"],"award-info":[{"award-number":["FIS PI16\/02057"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI15\/00298"],"award-info":[{"award-number":["PI15\/00298"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["CP14\/00133"],"award-info":[{"award-number":["CP14\/00133"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ISCIII-RETIC REDinREN","award":["RD16\/0009"],"award-info":[{"award-number":["RD16\/0009"]}]},{"name":"Sociedad Espa\u00f1ola de Nefrolog\u00eda and Miguel Servet","award":["MS14\/00133"],"award-info":[{"award-number":["MS14\/00133"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/ndt\/gfy089","type":"journal-article","created":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T08:07:06Z","timestamp":1521274026000},"page":"1284-1289","source":"Crossref","is-referenced-by-count":8,"title":["Enzyme replacement therapy dose and Fabry nephropathy"],"prefix":"10.1093","volume":"33","author":[{"given":"Alberto","family":"Ortiz","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dolores","family":"Sanchez-Ni\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"key\n\t\t\t\t20180801040006_gfy089-B1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12967-016-1049-8","article-title":"Increased urinary CD80 excretion and podocyturia in Fabry disease","volume":"14","author":"Trimarchi","year":"2016","journal-title":"J Transl Med"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B3","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B6","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B9","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.medcli.2016.09.047","article-title":"Diagnosis and treatment of Fabry disease","volume":"148","author":"Ortiz","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy\u2014new insights in efficacy of different dosages","volume":"33","author":"Kr\u00e4mer","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gim.2016.117","article-title":"Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature","volume":"19","author":"Pisani","year":"2017","journal-title":"Genet Med"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1681\/ASN.2015030337","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up","volume":"27","author":"Lenders","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch","volume":"25","author":"Weidemann","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.medcli.2017.03.054","article-title":"Differences between agalsidase \u03b1 and agalsidase \u03b2 in the treatment of Fabry disease","volume":"149","author":"P\u00e9rez-L\u00f3pez","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B19","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.ymgme.2016.11.292","article-title":"A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells","volume":"120","author":"Ramaswami","year":"2017","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B20","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ymgme.2015.12.307","article-title":"Comparison of integrated white blood cell alpha-galactosidase A activity exposure between every-other-day orally administered migalastat and biweekly infusions of agalsidase beta or agalsidase alfa","volume":"117","author":"Johnson","year":"2016","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B22","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2013the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10545-015-9845-5","article-title":"A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease","volume":"38","author":"Schiffmann","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/GIM.0b013e318133fb1b","article-title":"The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease","volume":"9","author":"Clarke","year":"2007","journal-title":"Genet Med"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B26","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/DDDT.S80928","article-title":"Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease","volume":"9","author":"Gol\u00e1\u0148","year":"2015","journal-title":"Drug Design Dev Ther"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B27","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.2147\/DDDT.S93371","article-title":"Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered","volume":"9","author":"Ortiz","year":"2015","journal-title":"Drug Design Dev Ther"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B28","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B29","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PloS One"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B31","article-title":"Canadian Fabry Disease Initiative Study (CFDI): 8 year outcomes of a randomized controlled trial of enzyme replacement therapy (ERT)","author":"West","year":"2016","journal-title":"Garrod Symposium"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.medcli.2017.05.016","article-title":"Reply","volume":"149","author":"Ortiz","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B35","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PloS One"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/8904_2015_483","article-title":"Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease","volume":"25","author":"Goker-Alpan","year":"2016","journal-title":"JIMD Rep"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B38","doi-asserted-by":"crossref","first-page":"e0128351","DOI":"10.1371\/journal.pone.0128351","article-title":"Rapid immunochromatographic detection of serum anti-\u03b1-galactosidase A antibodies in Fabry patients after enzyme replacement therapy","volume":"10","author":"Nakano","year":"2015","journal-title":"PloS One"},{"key":"key\n\t\t\t\t20180801040006_gfy089-B39","doi-asserted-by":"crossref","first-page":"e0173358","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PloS One"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/33\/8\/1284\/25198532\/gfy089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T21:48:52Z","timestamp":1570916932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/33\/8\/1284\/4976525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,4,18]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy089","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,4,18]]}}}